Choosing Between Semaglutide and Tirzepatide for Microdosing From a pharmacology standpoint, semaglutide is a pure GLP-1 receptor agonist , while tirzepatide is a dual GIP/GLP-1 agonist that activates both GIP and GLP-1 receptors.[2,4] That dual mechanism likely contributes to tirzepatides strong weight-loss results at full doses compared with semaglutide in head-to-head and indirect comparisons.[2,7] In the context of microdosing: Some clinicians and patients feel that microdosing tirzepatide provides robust appetite control even at relatively low doses, though this is based largely on real-world experience rather than large trials
You don't have that claims data
If you are not comfortable with self-injection, you are welcome to return to our office for each dose
But the Croaie SMGT-GLP-1 Nano Microneedle Patch has given me new hope
More approvals could push prices to Tier 3 Health Canada is currently reviewing seven other submissions for generic semaglutide by different companies and expects to make regulatory decisions on more of these submissions in the coming weeks and months [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html]
External links [edit] "Ghrelin Receptor"
